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Abstract
The trematode Fasciola hepatica is responsible for chronic zoonotic infection globally.
Despite causing a potent T-helper 2 response, it is believed that potent immunomodulation
is responsible for rendering this host reactive non-protective host response thereby allow-
ing the parasite to remain long-lived. We have previously identified a growth factor, FhTLM,
belonging to the TGF superfamily can have developmental effects on the parasite. Herein
we demonstrate that FhTLM can exert influence over host immune functions in a host
receptor specific fashion. FhTLM can bind to receptor members of the Transforming
Growth Factor (TGF) superfamily, with a greater affinity for TGF-β RII. Upon ligation
FhTLM initiates the Smad2/3 pathway resulting in phenotypic changes in both fibroblasts
and macrophages. The formation of fibroblast CFUs is reduced when cells are cultured
with FhTLM, as a result of TGF-β RI kinase activity. In parallel the wound closure response
of fibroblasts is also delayed in the presence of FhTLM. When stimulated with FhTLM
blood monocyte derived macrophages adopt an alternative or regulatory phenotype. They
express high levels interleukin (IL)-10 and arginase-1 while displaying low levels of IL-12
and nitric oxide. Moreover they also undergo significant upregulation of the inhibitory recep-
tor PD-L1 and the mannose receptor. Use of RNAi demonstrates that this effect is depen-
dent on TGF-β RII and mRNA knock-down leads to a loss of IL-10 and PD-L1. Finally, we
demonstrate that FhTLM aids newly excysted juveniles (NEJs) in their evasion of antibody-
dependent cell cytotoxicity (ADCC) by reducing the NO response of macrophages—again
dependent on TGF-β RI kinase. FhTLM displays restricted expression to the F. hepatica
gut resident NEJ stages. The altered fibroblast responses would suggest a role for damp-
ened tissue repair responses in facilitating parasite migration. Furthermore, the adoption of
a regulatory macrophage phenotype would allow for a reduced effector response targeting
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juvenile parasites which we demonstrate extends to an abrogation of the ADCC response.
Thus suggesting that FhTLM is a stage specific evasion molecule that utilises host cytokine
receptors. These findings are the first to clearly demonstrate the interaction of a helminth
cytokine with a host receptor complex resulting in immune modifications that facilitate the
non-protective chronic immune response which is characteristic of F. hepatica infection.
Author Summary
Parasitic worms, helminths, can cause long-lived chronic infection in many hosts that they
infection. The liver fluke, Fasciola hepatica, is one such parasite causing global infection of
both humans and animals. F. hepatica exerts an influence over the immune system such
that it avoids effectormechanisms and prevents the development of effective immunity.
Here we characterise a molecule—FhTLM—derived from juvenile parasites that is similar
to the regulatory cytokine TGF-β. We show that FhTLM will bind to host TGF-β receptors
with a reduced affinity when compared with mammalian TGF-β. Despite this FhTLM can
induce Smad2/3 signalling in host leukocytes,which is key to initiating gene transcription.
Phenotypically FhTLM causes fibroblasts to slow their growth and replication response
resulting in slower wound healing. Importantly FhTLM induces a macrophage phenotype
that resembles a regulatorymacrophage phenotype identified in other species undergoing
helminth infection. Finally we Our work highlights the potential of FhTLM to play impor-
tant roles in controlling host immunity when initially infected with juvenile parasites,
thereby preventing the development of effective immunity.
Introduction
The trematode Fasciola hepatica is capable of establishing chronic infection in multiple hosts
that can last for many years. In terms of animal infections F. hepatica is highly prevalent within
sheep, cattle and goats throughout temperate regions of the globe with varying levels of infec-
tion reported from 30%-70%[1]. This problem is compounded by a growing degree of resis-
tance against what has been the drug of choice for combating infection, triclabendazole [2].
F. hepatica however is not solely an animal problem as it also has growing implications for
human health with large endemic foci of infectionwithin South America and the Middle East
[3]. Crucially, there has now been a reported case of triclabendazole resistant parasites causing
human infection [4]. As such F. hepatica has been added to the list of emerging zoonotic dis-
eases [5]. In response to infection an extremely polarised T-helper (Th) 2 response character-
ised by high levels of IgG1, IL-4 and eosinophilia. Despite the magnitude of this response
naturally infected animals fail to develop immunity [6] and efforts at experimental vaccination
have thus far demonstrated that a mixed Th2/Th1 profile is required to achieve a reduction in
parasite burdens, egg outputs and liver damage [7]. As infection progresses the Th2 response
switches to a characteristic regulatory response—this is denoted by high levels IL-10 and TGF-
β and suppression of antigen specific T-cells [8].
Much research has identified the nature and mode of action of parasite derived immuno-
modulators. Chief amongst these is the aforementioned cathepsin L1 which has also been
shown to suppress Th1 cytokine secretion. Cathepsin L1 has also been shown to cleave CD4
from the surface of lymphocytes [9] and prevent antibody-dependent cell cytotoxicity (ADCC)
from killing newly excysted juvenile (NEJ) parasites [10]; one of the fewmechanisms known to
F. hepatica Interactions with TGF Signalling
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kill NEJs. More recently Donnelly and colleagues have shown multiple modes of immunosup-
pression involving a family of helminth defence molecules, similar to host defence peptides
that are capable of suppressing macrophage activation and B-cell cytokine responses [11]; pro-
viding evidence parasite for mimicry.
Another family of proteins which has demonstrated conservation between host and multi-
ple parasites is the Transforming Growth Factor (TGF) superfamily [12]. Members of this pro-
tein superfamily have been shown to predominantly play roles in body patterning, optimal
sexual development and reproductive success. Members of this family have been found in free-
living and parasitic worms including Schistosoma mansoni [13], S. japonicium [14], Ancylos-
toma caninum [15] and Caenorhabditis elegans [16]. We have recently demonstrated that the
F. hepatica contains a TGF-like molecule which we termed FhTLM [17]. Previously we have
shown that the expression of FhTLM was restricted to the NEJ stage. Further to this we have
provided evidence that recombinant FhTLM could enhance motility and survival of NEJs
while increasing the rate at which eggs underwent embryonation. Members of the TGF super-
family have been ascribedmany roles including within leukocytes. TGF-β is a requirement for
the development of both Th17 and Treg cell subsets with the levels IL-6 playing a crucial role
in dictating the fate of these cells. TGF-β secreted from Treg cells or other sources can have an
anti-proliferative effect on T-cells after TCR stimulation. Macrophage responses to TGF-β are
broadly known to result in anti-tumouricidal [18] and anti-inflammatory [19] macrophages.
Recently, the effect of TGF-β has been shown to direct the effects of myeloid suppressor cells in
Nippostrongylus brasiliensis infection thus controlling Th2 immunity within the lung [20].
TGF-β is also known to be crucial to development of fibrosis, this response can be serve to pro-
mote pathology via hypertension during S.mansoni infection [21]. Studies onHeligmoso-
moides polygyrus suggests that there is a protein(s) which can bind the mammalian TGF-
receptor complex and initiate a Smad2/3 signalling program [22]. ThisH. polygyrus derived
antigen was found to upregulate FoxP3 expression within naïve T-cells, directly generating
Tregs; a finding that explains the protective effect ofH. polygyrus in lung inflammation [23].
Given the above and our own findings with regard to FhTLM we sought to determine if
FhTLM could directly interact with the native receptor complex and initiate a phenotype. To
begin this process we determined if FhTLM could generate a response signal using a luciferase
reporter cell line and physically bind host TGF-β RI and RII. FhTLM initiates a Smad3 signal
and can alter the responses of fibroblasts in a TGF-β RI kinase dependent fashion. Moreover
when used to activate macrophages the response to FhTLM and the resultant phenotype
resembled a regulatorymacrophage rather than the helminth-linked alternatively activated
macrophage; with high levels of IL-10 and PD-L1 and moderate arginase-1 activity. These
processes occurred in a tgf-βRIIdependent fashion as demonstrated by siRNA knockdown.
Finally, the FhTLM macrophage phenotype was incapable of killingNEJ parasites by ADCC
demonstrating that this stage specific parasite protein might elicit non-protective responses
from resident cells within the intestinal phase of infection.
Results
F. hepatica expresses a growth factor similar to TGF-β
We have recently shown that the trematode parasite Fasciola hepatica contains three ligand
members of the transforming growth factor superfamily [17]. These include two bonemorpho-
genic proteins (BMPs) and an activin-likemolecule which we have terms F. hepatica TGF-like
molecule, FhTLM. We have demonstrated a restricted pattern of expression within the parasite
with the highest level of expression within the newly excysted juvenile that emerges within the
intestine of hosts. To determine if FhTLM is a bioactivemolecule similar to TGF-β we assessed
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its activity in a reporter assay [24]. A dose response analysis suggests that FhTLM can indeed
generate a positive luciferase signal and when compared to a TGF-β1 standard curve it would
suggest that FhTLM has a lower degree of bioactivity in this assay when compared with mam-
malian equivalents (Fig 1A). We were also able to demonstrate a similar activity within crude
parasite homogenate (LFH) which required higher concentrations to induce comparable
responses (S1 Fig). Initial attempts to use a monoclonal antibody to inhibit FhTLM activity did
not demonstrate inhibitory capacity. However, a polyclonal anti-sera raised with broad speci-
ficity was found to reduce the activity of FhTLM in the same bioassay in a dose dependent
manner (Fig 1B). To ensure the effects of FhTLM were dependent on ligand-receptor based
interactions we sought to determine if FhTLM could bind either of the bovine TGF-β RI or RII.
We cloned and expressed fusion proteins comprised of the bovine TGF-β RI and RII extracel-
lular domain fused to the human IgG1 Fc domain (S1 Table). Using these proteins we per-
formed a comparison between the binding of these fusion proteins to FhTLM and human
TGF-β1 (Fig 1C & 1D –note differences in Y-axis scale). Using both fusion proteins we could
confirm that human TGF-β1 could bind the bovine receptors RI and RII. More interestingly
we also confirmed that FhTLM could cause the binding of both fusion proteins with a greater
affinity for TGF-β RII-Fc, which is similar to the reported affinity of TGF-β RII with TGF-β1
elsewhere [25, 26]. Final confirmation of the greater affinity of TGF-β RII with FhTLM was
confirmed by repeating the above assays but with the inclusion of increasing concentrations of
KSCN after initial addition of fusion proteins to the plate. A greater concentration of KSCN
was required to disassociate the interaction between FhTLM with TGF-β RII-Fc when com-
pared with TGF-β RI-Fc (Fig 1E). Moreover when we tested the affinity of FhTLM for either
TGF-β RII-Fc or TGF-β RI-Fc in a competition assay we were able to demonstrate that FhTLM
was only moderately able to reduce the binding of free TGF-β RII-Fc or TGF-β RI-Fc to immo-
bilised TGF-β1 reducing binding to TGF-β RII-Fc and TGF-β RI-Fc by 46% and 42%, respec-
tively. In comparison TGF-β was able to reduce binding of FhTLM to TGF-β RII-Fc and TGF-
β RII-Fc by 50% and 22%, respectively, as comparable doses (Fig 1F & 1G).
FhTLM drives Smad2/3 signalling with delayed kinetics
The TGF-β receptors are G-protein coupled receptors and after ligand binding heterodimers of
TGF-β RI and RII are formed. The resultant phosphorylation of this receptor complex triggers
movement of the signalling proteins phosphorylated (p)Smad2/3 into the nucleus where gene
transcription is initiated [27]. To determine if FhTLM was capable of driving Smad2/3 signal-
ling after engagement with the receptor complex we used primary bovine peripheral blood
mononuclear cells (PBMCs) in a stimulation assay to measure the extent of co-localisation of
pSmad2/3 with the nucleus. Given the differences we noted above between activity of recombi-
nant FhTLM in our luciferase assay and the binding data determined from our receptor fusion
protein assays we conducted a dose response curve for bovinemacrophages using IL-10 as our
readout to determine the optimal working concentration (S2 Fig). PBMCs were stimulated for
between 3 and 4hrs, fixed and stained with DAPI (Fig 2A top row), anti-pSmad2/3-FITC (Fig
2A middle row) and the percentage of co-localisation (or pSmad2/3 positive cells) was deter-
mined (Fig 2A bottom row). TGFβ clearly drives pSmad2/3 signalling in this setting with 28%
(±4.1%) of cells being pSmad2/3 positive at 3hrs post-stimulation with a small, but not signifi-
cant decrease, at 4hrs to 22.4% (±5.3%). Interestingly when we initially examined cells stimu-
lated for 3hrs with FhTLM we found only 10.7% (±1.9%) of cells positive which was not
significantly increasedwhen compared to our controls [6.8%(±2.5%)]. However, when we
extended our analysis to 4hrs we found that FhTLM induced pSmad2/3 in 15.8% (±2.9%) of
cells which was significantly different when compared to controls [5.4% (±3.4%)]. A recent
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Fig 1. FhTLM binds to and initiates mammalian host signalling pathways. (A) FhTLM was used to
stimulate the TGF-β responsive cell line at the indicated doses. Relative light units (RLU) were converted to
equivalent TGF-B concentration by comparison with a TGF-β standard curve. (B) This activity was inhibited by
polyclonal serum raised against TGF-β. Plate-bound FhTLM was detected using the recombinant fusion
proteins (C) bovine TGF-B R1-Fc and (D) bovine TGF-B RII-Fc. Results are reported as optical densities (OD)
at 450nm. (E) Avidity of receptor-FhTLM interactions were measured using KSCN and presented as OD as a
function of increasing KSCN molarity. (F) and (G) FhTLM and TGF-β, respectively, were used to coat ELISA
plates (400ng/mL) overnight. Thereafter TGF-β1 and FhTLM were used in increasing concentrations shown to
block the interaction of TGF-βRI-Fc or TGF-βRII-Fc. Data presented are means +/- SD of triplicates,
experiments were repeated three times with similar results.
doi:10.1371/journal.ppat.1005991.g001
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analysis of the bovine il10 promoter within our lab has indicated a role for GATA1 in driving
il10 expression. Furthermore GATA1 has been in implicated in anti-helminth immunity in
previous studies usingNippostrongylus brasiliensis [28] and S.mansoni [29]. We subjected
PBMCs to a 4hr stimulation as above and then determined the levels of GATA1 co-localisation
and found that both TGF-β (11%±1.3%) and FhTLM (6.1%±1.4) could induce significantly
more GATA1 co-localisation in PBMCs when compared to controls (4.9%±1.1). Our results
clearly demonstrate that FhTLM can act to induce both direct and indirect transcription factors
in primary host PBMCs.
FhTLM alters fibroblast growth dynamics
Characterisation of TGFβ demonstrated a profound an anti-proliferative and developmental
effect on multiple cell types [30–35]. In an effort to ascribe a phenotype to the effects of
FhTLM we performedCFU assays using the NIH 3T3 fibroblast line. Cells were seeded at a
density of 6 cells/petri dish and incubated for 10 days. This was done in the presence of TGF-β
or increasing concentrations of FhTLM (2.5, 25, 200 ng/mL). CFUs that formed were counted
Fig 2. FhTLM can initiate transcription factor activation in primary host leukocytes. Naïve bovine
PBMCs were incubated with FhTLM (200ng/mL) and subsequently prepared for immunoflouresence (A) to
detect (B) Smad2/3 and (C) GATA1. (A) The upper row are cells stained with DAPI, middle row with anti-
Smad2/3-FITC, and bottom row iIn both panels, the columns represent (from left to right) unstimulated
PBMCs, TGF-β1 stimulated PBMCs, and FhTLM stimulated PBMCs. Following staining cytospins were
examined at 40X magnification and the number of positive cells (i.e. FITC overlaid on DAPI) were calculated.
This analysis was conducted over time for Smad2/3 (B) and at 3hrs for GATA1 (C). Data presented are
means +/- SEM of triplicates, experiments were repeated three times with similar results. Results were
analysed using a 1-way Anova and statistical significant differences are indicated on the graphs, *P<0.05 or
**P<0.01.
doi:10.1371/journal.ppat.1005991.g002
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and our results clearly show a significant decrease in number of CFUs that formed when higher
doses of FhTLM were used (Fig 3A). 25ng/mL of FhTLM was sufficient to reduce the number
of CFUs to comparable level as seen on those incubated with TGF-β (128.3±6.173 vs. 129.7
±19.10). To further determine the effects of FhTLM on fibroblast activity we performed in
vitro scratch assay/wound closure experiments. Confluent cells were scratched and imaged
before incubation for 24hrs with TGF-β or FhTLM. After 24hrs the wounds were imaged and
total area determined (Fig 3B). Expressing this area as % wound closure we found that both
TGF-β and FhTLM significantly reduced wound closure (P<0.01) [Ctrl = 67.77%±12.17 vs.
TGF = 47.95±4.906 vs. FhTLM = 44.47±7.235]. Decreased arginase-1 has been previously
shown to correlate with delayed wound resolution [36]. We determined the levels of arginase-1
in wounded cultures 24hr after incubation (Fig 3C). We confirmed that in cultures treated with
TGFβ or FhTLM the levels of arginase-1 were decreased suggesting an ability of FhTLM in
altering arginase-1 activity. We next using chemical inhibition to block the kinase activity of
TGF-β RI to determine if the effects of FhTLM are indeed TGF-β dependent and specific. As
can be seen in Fig 3B when cells were co-culturedwith the inhibitor SB- 431542 [37] during
formation of fibroblast CFUs the effect of both TGF-β and FhTLM were abolished. These
results suggest that FhTLM can both bind and initiate a specific signal via the TGF-β receptor
complex.
FhTLM induces a regulatory macrophage phenotype dependent on
TGF-β RII
Having demonstrated a role for FhTLM in modulating cell growth and regulating the arginase
levels of these cells we sought to determine if the effects of FhTLM on arginase levels could be
extended to macrophages. The classical and alternative pathways for macrophage activity can
be broadly defined in terms metabolism of L-arginine either using iNOS or arginase following
stimulation with LPS/IFN-γ or IL-4, respectively [38]. We produced bovinemacrophages
using purified blood derived CD14+ monocytes; these were then stimulated with IL-4, LPS,
TGF-β or FhTLM. Our initial analysis confirmed that IL-4 and LPS act to induce arginase or
NO, respectively (Fig 4A & 4B). While FhTLM can induce a slight increase, similar to that seen
in response to induced TGF-β, in the levels of arginase-1 this was not significant when com-
pared with IL-4 but was significantly different when compared with the control. Similarly LPS
inducedNO but IL-4, TGF-β or FhTLM inducedmarginal levels in comparison. To further
determine if FhTLM could alter the phenotype of macrophages we measured IL-10 and IL-12.
Only LPS stimulation induced significantlymore IL-12 when compared to controls (Fig 4D).
However, both IL-4, TGF-β and FhTLM induced IL-10, raising levels significantly above con-
trols (Fig 4C). While TGF-β tended towards higher levels of IL-10 induction when compared
with L-4 this was not significant. Reports of a regulatorymacrophage phenotype in helminth
infection or in response to helminth products suggest that this cell population is distinct from
alternatively activated macrophages [39, 40] and in some cases it would appear to be indepen-
dent of arginase-1 [39]. These reports suggest that upregulation of mannose receptor (MR) and
PD-L1 serve as proxy markers for these cells. We determinedMR levels in stimulated cells by
immunofluorescence or PD-L1 levels of qPCR (Fig 4E & 4F). FhTLM significantly upregulated
MR expression compared to controls and the number of cells becomingMR+ after stimulation
was comparable to IL-4 treatment. However TGF-β, in comparison to both IL-4 and FhTLM,
was induced a higher number of MR+ cells [~60% vs 20%] (Fig 4E). When we examined PD-L1
expression only FhTLM and TGF-β were able to induced PD-L1 above levels seen in controls,
again with TGF-β inducing higher levels of PD-L1 compared to FhTLM [30 fold change vs 10
fold change] (Fig 4F).
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To determine what host factor confers specificity on interaction of FhTLM with bovine
macrophages we employed siRNA directed against the tgf-βRII. Primary bovine macrophages
were as standard, however at point prior to normal cytokine stimulation cells were transfected
with target siRNA or with scrambled siRNA, thereafter we measured changes in tgf-βRII levels
Fig 3. FhTLM changes fibroblast responses. FhTLM was included as an additive in fibroblast CFU cultures (A) or in wound repair assays (C).
(A) 3T3 fibroblasts were seeded at 6 cells/well in 6 well plates with the indicated additives. Cultures were incubated for 10 days, stained with
crystal violet and CFUs were counted. (B) Cultures as above were established but with the addition of the specific TGF-βRI activin receptor-like
kinase (ALK) inhibitor SB431542 (5μM). (C) 3T3 fibroblasts were seeded in 6 wells plates and grown to 80% confluence. Horizontal wounds
were introduced and wells imaged at T0 and again at T24. TGF-β or FhTLM were included post-wounding at the indicated concentrations.
Images were blinded and % wound closure was calculated as area of well visible at T24 relative to T0. (D) Cell lysates were collected from (C)
and arginase levels were determined by enzyme assay and reported as mU/106 cells. For A, B and C data represents means +/- SEM of 4–6
measurements and experiments twice were repeated with similar results. Data in D represent combined data from (C) with N = 8–12
measurements +/- SEM per treatment. Results were analysed using a 1-way Anova and statistical significant differences are indicated on the
graphs, P **P<0.01.
doi:10.1371/journal.ppat.1005991.g003
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Fig 4. FhTLM induces a part alternative part regulatory macrophage phenotype. FhTLM (200ng/mL) was used to
stimulate the bovine macrophages derived from blood monocytes. Thereafter levels of (A) nitric oxide (NO) levels, (B) arginase-
1 levels, (C) IL-10, and (D) IL-12 in matched samples. Data in A-D is collected from the same experiment. In separate
experiments using the same donors mannose receptor expression was also determined using immunofluorescence (E) and (F)
increases in PD-L1 mRNA expression levels were quantified. Data represents means +/- SEM of triplicate measurments and
experiments were repeated three times with similar results. Results were analysed using a 1-way Anova and statistical
significant differences are indicated on the graphs; *P<0.05, **P<0.01.
doi:10.1371/journal.ppat.1005991.g004
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over a 72hr time period.Our results show we could reliably suppress tgf-βRIImRNA levels up
to 24hrs post transfection (Fig 5A). We then proceeded to stimulate macrophages 6 hours after
knock-down,with FhTLM or TGF-β. Our results show that absence of tgf-βRIImRNA at the
time of cytokine treatment results in a reduced levels of PD-L1 being upregulated in response
to both FhTLM and TGF-β with knock-down reducing PD-L1 upregulation by 47% and 90%,
respectively (Fig 5B). While in the case of IL-10 induction,measured 54 hours post-transfec-
tion and 48hrs post-stimulation, we same similar reductions in the levels of IL-10 in response
to FhTLM and TGF-β (Fig 5C). These results strongly support the conclusion that the effects
of FhTLM are dependent on the host cytokine receptor complex TGF-β RI and RII, especially
when taken in together with our findings above showing that ALK inhibition also negated the
effects of FhTLM.
FhTLM can negate the effects of ADCC on juvenile F. hepatica
We have previously shown that FhTLM is selectively expressed within the newly excysted juve-
nile (NEJs) stage of F. hepatica infection [17]. NEJs are thought to be resident within the intes-
tine for only a number of hours before entering the peritoneal cavity and continuing on their
migration to the liver. Within the intestine, multiple type-2 effector responses could be active
including antibody-dependent cell cytotoxicity (ADCC).ADCC is one of the fewmechanisms
shown to actively kill F. hepatica and has previously been shown to target NEJs, both in vitro
and in vivo;moreover it has previously been shown to be a target of parasite immune evasion
mechanisms [10, 41, 42]. We sought to determine if FhTLM altered the macrophage compo-
nent of this process to benefit parasite survival. Using naïve donor macrophages we incubated
cells and NEJs in the presence of either immune or naïve sera. Thereafter viable parasites
were counted by visual inspection, as can be seen in Fig 6A the presence of macrophages plus
immune sera, but not non-immune sera, resulted in the death of NEJs and was accompanied
by induction of NO (Fig 6B). When macrophages were incubated with TGF-β or FhTLM prior
to addition of NEJs and sera a different outcome was recorded. As can be seen in Fig 6A both
TGF-β and FhTLM reduced the capacity of immune sera to induce ADCC-mediateddeath of
NEJs, this was also accompanied by a loss of NO production (Fig 6B).
We next determined if the effect of FhTLM was dependent on the TGF-β RI, via kinase
activity, pre-incubation of cells with the inhibitor SB-431542. Pre-incubation of macrophages
with inhibitor prior to TGF-β or FhTLM reversed the negative effect on cells and rescued
the ADCC response to NEJs in the presence of immune sera in comparison to cells pre-incu-
bated with vehicle only (Fig 6C). To accompany this we also found that the NO response was
restored in both TGF-β and FhTLM cultures in cells pre-incubated with inhibitor but not vehi-
cle only (Fig 6D). Thus our findings demonstrate that FhTLM alters the host macrophage phe-
notype, via TGF-β RI and RII, to evade ADCCkilling of NEJs.
Discussion
Multiple studies have shown that chronic infectionwith F. hepatica can be long lived and
accompanied by parasite-specific and non-specific immunosuppression [8, 43, 44]. As the host
progresses from a Th2 type response to a more regulatory response it is assumed that secretion
of IL-10 and TGF-β increases as a result of either T-cell phenotypic changes or the expansion
of T-regulatory cells. The parallel expansion of both Th2 and Treg populations has previously
been demonstrated in S.mansoni [45] and recent work in murine models of F. hepatica have
also demonstrated that infectedmice generate a FoxP3+ population of cells as infection pro-
gresses [46]; however the relevance of this to ruminant immune responses remains to be deter-
mined. All of these mechanisms would appear to be driven, or at executed, by the host as a
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Fig 5. FhTLM requires TGF-βRII to induce IL-10 and PD-L1. To access whether the effects of FhTLM on
macrophages was specific to interactions with the host TGF-β receptor complex we employed siRNA to
knock-down tgf-βRII expression. Primary macrophages were isolated and prior to stimulation were
transfected with siRNA against tgf-βRII using Lipofectamine. (A) Expression of tgf-βRII mRNA were
quantified by qPCR at the indicated timepoints post-transfection to monitor the effects of knock-down. At
12hrs post-transfection cells were treated with either FhTLM or TGF-β and TGF-β before IL-10 was
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measured 48hrs after stimulation (B) or PD-L1 was measured 6hrs after stimulation. All data is mean +/-
SEM of triplicate measurements, (A) is data from one donor animal presentative of three individuals and data
in (B) and (C) represent the means of 4 individual donor animals. Results in (B) and (C) were analysed using
a 1-way Anova and statistical significant differences are indicated on the graphs; *P<0.05, **P<0.01,
***P<0.001.
doi:10.1371/journal.ppat.1005991.g005
Fig 6. FhTLM reduces the capacity of macrophages to kill juvenile F. hepatica by ADCC. Macrophages were cultured from naïve donors as
described in the presence of FhTLM or TGF-β for 24hrs. Following this macrophages were incubated with newly excysted juveniles (NEJs) in the
presence of serum taken from naïve (non-immune) or experimentally infected, 13 weeks post-infection, animals (immune). After 6hr of incubation
dead parasites were counted (A) and levels of NO in the supernatant determined (B). Experiments were repeated to test the effect of TGF-βRI ALK
inhibitor, SB431542 (5μM),on macrophages before incubation with NEJs and serum and measurement of parasite killing (C) and NO levels (D).
Data in (A) and (B) were tested for statistical significance using a 2-way anova to determine effect of non-immune vs immune sera and between
PBS, FhTLM, and TGF-βmacrophage treatment. Data in (C) and (D) were tested using 1-way Anova to determine the effect of inhibitor on TGF-β or
FhTLM. **P<0.01 and ***P<0.001. Data displayed is mean +/- SEM and is representative of experiments conducted with 5 individual naïve
macrophage donors, using 5 technical replicates per animal.
doi:10.1371/journal.ppat.1005991.g006
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balance to minimise immunopathology. Here we demonstrate that F. hepatica can utilise a
host-exogenous cytokine/growth factor, FhTLM—previously shown to have developmental
functions, to direct the host immune system. Indeed this mechanism fits with previous patterns
identifiedwhereby for optimal host and parasite survival a balance of immune effectormecha-
nisms must be maintained, allowing parasite survival while avoiding immunopathology [47].
Our data demonstrates that FhTLM is capable of directly engaging TGF-β RI and RII in an
ELISA format which makes use of fusion proteins of RI and RII. This data helps to explain
the activation by FhTLM of the luciferase reporter. Indeed there are prior reports of parasite
derivedmolecules driving activation in this assay system previously [22]. What is apparent
from these data is that FhTLM has a) a higher affinity for TGF-β RII over RI and b) has a
lower binding capacity for either receptor when compared with human TGF-β1; this is further
evidenced by our competition data. This effect is seen again in the results of our luciferase
assay whereby FhTLM was needed in the ng/mL range to generate signals equivalent to those
seen in TGF-β in the pg/mL range. The higher affinity of TGF-β for TGF-β RI and RII is also
seen in mammalian systems [25, 26] and highlights the conservation between the two ligands
despite being phylogenetically distinct, demonstrating the close association amongst the para-
site and host. To ensure that the immunomodulatory capacity of FhTLM was not due to
binding but not initiating signalling from the receptor complex we examined the canonical
intracellular signallingmolecule Smad2/3. Using immunofluorescencewe can see that not
only does FhTLM drive p-Smad2/3 translocation to the nucleus but also does so at slower
rate when compared to mammalian TGF-β, again in line with our findings from our binding
experiments. It took 4hrs of stimulation with FhTLM to drive a p-Smad2/3 signal distinct
from background when compared with the higher translocation rate and shorter time period
required in response to TGF-β.
TGF-β is pleiotropic in terms of its effects being implicated in developmental processes,
anti-proliferative in a context dependent fashion, responsible for fibrosis, and key to differenti-
ation of two distinct CD4+ T-helper subsets. TGF-β is known to be anti-proliferative in terms
of fibroblasts [30, 34, 35] and we confirm this finding here and also demonstrate that FhTLM
can cause a similar response which is also dependent on TGF-β RI kinase activity. FhTLM
reduced the number of CFUs formed to a similar rate of TGF-β over a 10 day period. Likewise
when included as a growth factor in in vitro wound assays we found that FhTLM, like TGF-β,
reduced the rate of wound closure. The role of TGF-β in wound responses is still disputed with
some reports finding a positive or negative role dependent on the phase of wound resolution in
which it is examined. A recent study however determined that arginase-1 was crucial for heal-
ing in murine model wounding [36] and here we found that in parallel with reducing wound
closure FhTLM also reduced the cellular levels of arginase-1. Campbell et al [36] found the
reduction in arginase-1 levels also resulted in a reduction in pro-inflammatory cell recruitment,
including macrophages. The benefits in delayed wound healing during a parasite infection are
not apparent however given the migratory nature of F. hepatica infection, it could be speculated
that reducing the rate at which wounds or migratory paths caused by the parasite are healed
may confer a benefit to the parasite. The parasite excysts within the intestine and migrates into
the peritoneal cavity where it gains access to liver before moving to bile ducts [48]. As the para-
sites migrate through the intestine they formed a cavity around themselves which would
require healing post migration. The delay in healingmay increase the rate of successfulmigrat-
ing NEJs; it is already knwon that NEJs secrete proteases to digest surrounding tissue to facili-
tate their movement [49].
Given the context specific effects of TGF-β we sought to determine its effects on other cell
types. Studies suggest that helminth infection [39] and a recombinant helminth immunomodu-
lator [40] can induce a macrophage phenotype that is distinct from the alternatively activated
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phenotype that is normally associated with helminth infection [50]. Our data demonstrated a
subtle yet significant rise in arginase-1 levels following FhTLM, in contrast to our results in the
fibroblast experiments, and no increase in NO and in comparison to the strongly polarising
effect that IL-4 has on these readouts the results were not striking and more akin to the
response to TGF-β. This pattern concurs with the findings of Smith et al.,[39] who found a hel-
minth elicited macrophage population could protect from colitis but in an arginase-1 depen-
dent manner. We next examined the cytokine profile, IL-10 and IL-12, of these cells we found
a more pronounced effect of FhTLM. FhTLM could upregulate IL-10 while also suppressing
the expression of IL-12, this has been a reported feature of regulatorymacrophages for some
time [51]; again this pattern of responses beingmore similar to TGF-β than IL-4. Moreover
mRNA expression of PD-L1 and the number of mannose receptor positive cells were signifi-
cantly upregulated in FhTLM or TGF-β treated macrophages only. During infectionwith Tae-
nia crassiceps PD-L1 has been shown to suppress T-cell responses and neutralisation of PD-L1
on macrophages from infectedmice abrogated their suppressive capacity [52]. Recently, an
Ancanthocheilonema viteae derived immunomodulatorywas shown to induce macrophages
with high levels of expression of IL-10 and PD-L1 capable of reducing signs of colitis in mice
after cell transfer [40]. The mannose receptor (CD206) has previously been shown to be upre-
gulated on regulatorymacrophages from a variety of settings [53, 54] including controlling
their role in regulating inflammatory cytokine release in Pneumocystis infection [55] and
endotoxin-induced lung injury [56]. We found the effects of FhTLM on PD-L1 and IL-10 to be
dependent on tgf-βRII expression, as use of siRNA resulted in a loss of their expression follow-
ing stimulation. Given the effects of FhTLM on macrophages and the restricted expression of
FhTLM to NEJs within the parasite itself; we sought to determine the effects of FhTLM on a
NEJ targeting effectormechanism—ADCC.ADCChas been shown to kill NEJs when using
cells from cattle [41], rats [42], and mice [10] but not sheep [57].This is thought to be as a result
of a lack of NO generation in sheep macrophages. Here we demonstrate that bovinemacro-
phages, in the presence of immune sera, kill NEJs and release NO into the supernatant. More-
over the culture of macrophages with FhTLM or TGF-β prior to this assay effectively removed
the killing phenotype and reduced the levels of NO. When these assays were repeated in the
presence of the TGF-β RI kinase inhibitor the ADCC effect was rescued and parasites were ren-
dered non-viable and NO levels were restored, again showing the effects of FhTLM to be TGF-
β receptor dependent.
The expression of TGF-β homologues within helminth parasites has been previously identi-
fied [58] however this, to our knowledge, is the first full description of the suppressive effect of
a recombinant helminth TGF-β homologue on its host immune system. Our findings indicate
a role for FhTLM in the modulation of host macrophages to avoid a well-recognisedmecha-
nism of killing ADCC.The complete function of FhTLM during infection has yet to be
explored but the on-going development of stable gene silencing techniques in F. hepatica will
make this achievable [59]. A loss-of-function approach would be the best method to approach
this subject, however there exists a number of hurdles, metacercariae have yet to be successfully
treated with RNAi and as such NEJs treated with RNAi would need to be transplanted into the
intestines of suitable hosts. The macrophage response to surgery has been shown to tend
towards alternative activation, thus attempting to analyse the immune phenotype in such cir-
cumstances may prove difficult.A second complicating factor are the parasite-intrinsic effects
of FhTLM [17], knock-out of FhTLM may yield a near-lethal or lethal phenotype, for reasons
unrelated to host immunity, again complicating the analysis. A system for conditional gene
targeting within the parasite metacercariae would best allow for natural infection and thus a
faithful analysis of the resulting immune response; however these tools do not yet exist. Imple-
mentation of this technologywill aid us in answering unresolved questions surrounding exact
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timing of FhTLM expression within the intestine of hosts, the full range of target cells and
whether the effects of FhTLM are confined both physically and temporally confined to the
intestine.
Methods
FhTLM and receptor fusion protein production
We have previously described the cloning and expression of FhTLM [17]. A pET28-based con-
struct (Novagen) was used to express a 6XHis-Tagged protein in BL21 E. coli (Novagen) using
kanamycin and chloramphenicol to select for transformed bacteria. Recombinant protein was
purified using a Nickel resin column (Sigma-Aldrich). Recombinant proteins were subject to
two rounds of phase separation prior to use [60]. To generate the receptor-fusion proteins the
bovine TGFβRI extracellular domain sequence from nucleotide (nt) +88 to +331 and TGFβRII
extracellular domain sequence from nt +139 to +453 relative to the translation initiation site
(+1) were PCR amplified using specific primers. Using a forward primer with a NCOI restric-
tion site incorporated and reverse primer with a Bg1II restriction site incorporated for TGFβRI
and forward primer with an EcoRI restriction site incorporated and reverse primer with a
Bg1II restriction site incorporated for generation of TGFβRII (See S1 Table). The amplified
extracellular domains of TGFβRI was sub-cloned into theNCOI and Bg1II and TGFβRII ED
into EcoR1 and Bg1IImulti cloning site of the pFUSE-hIgG1-Fc2 vector (InvivoGen, UK)
respectively. Following ligation and confirmation of insertion plasmids were used to chemically
transform E. coli DH5α cells. The transformed cells were grown on LB agar plates supple-
mented with 50μg/ml Zeocine (InvivoGen, UK) at 37°C overnight. Plasmid was purified and
used to transfect mammalian HEK-293 cells (Invivogen UK) maintained in DMEM (Sigma
Aldrich) supplemented with 10% FCS (Sigma Aldrich), 100 μg/ml penicillin, 100 μg/ml strep-
tomycin and grown to 80% confluency. Transfection with recombinant plasmids was carried
out using jetPRIMEDNA and siRNA transfection reagents (Polyplus-transfection, USA) as
per manufacturer’s instructions. The day before transfection cells were seeded into 6 well cul-
ture plate at 2x105 cells /well, DMEMmediumwere added to final volume of 2ml per well and
incubated at 37°C overnight 5% CO2. 2 μg of plasmid was diluted into 200 μl of jetPRIME
buffer and 4 μl of jetPRIMEwere added to each well for transfection. The transfectionmedium
were replaced with complete DMEMmedium after 4 hrs and incubated at 37°C for 72 hrs. A
positive control GFP reporter plasmid, Pc-gfp-c2 (Clontech), was used in parallel to confirm
transformation. After 72 hrs the positive controls was assessed under an inverted microscope
(LEICADMIL). Positive cells were cloned under limiting dilution conditions, using zeocine
(InvivoGen) as a selective.
Direct TGF-β receptor-fusion and competition assays
96-well plates was coated with 50 μl of hTGF-β1 or FhTLM, concentration indicated on figures,
at room temperature overnight. The plate was washed three times with 0.05% Tween/PBS.
Additional protein binding site were blocked by adding 200 μl of 4% BSA-PBS and incubated-
for 1 hr at room temperature. TGFβ-RI and RII Fc fusion proteins were used at 1.25μg/mL and
supernatant from non-transfectedHEK were used as negative control and added to the wells of
the plate and incubated for 1 hr at room temperature. HRP-conjugated Anti-human IgG1 Ab
(HP6070, Life Technology) at a concentration of 5 μg/ml. Colour was developedwith TMB
substrate and the reaction was stopped with 1% HCL; absorbance was measured at 450nm
using micro-plate reader (LT-4000, Labtech, UK).
To estimate the avidity of the FhTLM interaction with Fc fusion proteins of the bTGFβ-
RIED and RIIED, potassium thiocyanate (KSCN) was introduced into the ELISA to disrupt the
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binding between the bovine receptors and the recombinant FhTLM protein. ELISA was per-
formed as stated above using FhTLM as coating antigen at concentration of (500 ng/ml). After
addition and incubation with (1.25 μg/ml) of Fc fusion proteins, different concentrations (1, 2,
3, 4, 5 and 0 M) of KSCNwere added to each well and incubated for 1 hr at RT. Thereafter the
binding and optical densities were measured as above. To determine the extent of competition
between FhTLM and TGF-β in the context of binding to receptor fusion proteins, FhTLM or
TGF-β were coated on plates at 400ng/mL. After this the opposite increasing concentrations of
competing protein were incubated with the Receptor-Fc fusion in solution at 37°C for 1hr,
then added to the plate and the ELISA proceeded as above.
Luciferase Assay
Mink Lung epithelial cells (MLECs—a gift from Prof D Rifkin,New York University) were
maintained in T25 flask (Sarstedt) containing 5 ml of Dulbecco’s modifiedEagle’s Media
(DMEM) (Sigma-Aldrich) supplemented with 10% of heat inactivated fetal calf serum (Sigma-
Aldrich), penicillin (100 U/ml), streptomycin (100 U/ml), L-glutamine and 200 μg/ml, G418
(Sigma-Aldrich). For use in luciferasemeasurements cells were used at a concentration of
1.6x106 cells/ml. The suspension was plated in 96 well tissue culture plates (Sarstedt) 100 μl/
well. The culture plate was incubated at 37°C, 5% CO2 overnight for optimal cell attachment.
Proteins including a TGF-β standard curvewere added to cells in DMEMwith 0.1% BSA.
Luciferase was measured the luciferase Assay (Promega) on a BMG luminometer as per Abe
et al [24].
Macrophage Culture
Whole bloodwas collected under terminal exsanguination from healthy donor animals under
a Home Office regulated schedule 1 procedure. CD14+ cells were isolated and cultured as
before [61] IL-4 was used at 20ng/mL, LPS was used at 100μg/mL while FhTLM was either
used at the indicated dose or 200ng/mL. Cells were stimulated for 6hr for RNA isolation or
48hrs for collection of supernatants and cell lysates.
RNAi knock-down of tgfβRII (NM_001159566.1) was conducted using the methods of Jen-
sen et al [62] Briefly, siRNA oligos were designed by Sigma Aldrich and used at a final concen-
tration of 100nM. Macrophages were cultured to maturity in 48 well plates at a density of 1 x
105 cells and after 10 days were transfected with JetPrime media was replaced after 24hrs. Cells
were tested for knock-down beginning at a further 24hrs after media change this using PCR
primers designed against tgfβRII;Forwardprimer 5’ -GGACTATGAGCCTCCGTTCG- 3’ and
reverse primer 5’–GGTTCCAGGAAGCATCGTCA- 3’. Alternatively, once an optimum time
post-transfectionwas selected– 12hrs—stimulation was conducted.
Fibroblast cultures and wound healing assay
The fibroblast cell line NIH 3T3 (A gift from Dr Janet Daly University of Nottingham) was
routinely maintained and to conduct the scratch assay published methods were used. Briefly,
3x105 cells were seeded into 6 well plates and incubated overnight. To scratch the monolayer, a
linear scratch was made to the fibroblasts from the top of the well to the bottom using a 20μl
pipette tip at time 0; plates were then incubated with the indicated proteins for 24hrs. Images
of scratches were obtained using an inverted light microscope set to 5 x magnification. Lecia
imaging software (leicra microsystems LTB Milton Keynes UK) was used to acquire digital
images. ImageJ, was used to analyse the images (version 1.49v fromNational Institutes of
Health, USA). Scratch areas were measured and compared by a blinded operator independent
to the culture treatments for each well.
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To conduct the CFU assay 6 cells/well were seeded in a 6-well plate, thereafter proteins were
added and plates incubated for 10 days. Plates were stained with 0.5% crystal violet and imaged
as above. CFUs were determined per well by an operator blinded to treatments before data
analysis. In some experiments cells were co-culturedwith SB-431542 a TGF-β RI kinase inhibi-
tor (Tocris) and TGF-β or FhTLM with inhibitor at a final concentration of 5μM. Inhibitor
stocks were prepared in DMSO and vehicle controls were prepared using an appropriate com-
parative dilution of DMSO.
Immunofluorescence
For immunofluorescence staining cells were isolated and stimulated as above but grown on
coverslips (Corning). Following stimulation plates were centrifuged at 300xg for 10 min follow-
ing incubation, to collect cells on the cover slips. Medium were removed and cells were washed
three times with 1XPBS. PBMCs were then fixed by in 4% paraformaldehyde for 15 min at
room temperature and washed with 1XPBS. Afterward, cells were permeabilized for 10 min at
room temperature with 0.5% Triton X-100 in PBS and washed with PBS. Cells were incubated
for 1 hr at room temperature with a 1:100 dilution of primary polyconal rabbit anti-GATA1
(Santa Cruz sc-13053) or goat anti-pSmad2/3 (Santa Cruz sc-11769) or mouse anti-mannose
receptor (ThermoFisher 2G11). After extensive washing with PBS, the cells were incubated for
1 h at room temperature in the dark with 1:1000 dilution of secondary anti-IgG-FITC. Slides
were then washed with PBS, mounted with Vectashield (Vector Labs Ltd., UK) containing
DAPI staining reagent. Images were captured using Leica DM500B microscope and DFC
350FX camera (LeicaMicrosystem Ltd., UK) using X40 and X63 magnification.
Cytokine analysis, enzyme assays, qPCR
ELISAs or paired antibodies were used to detect cytokines were conducted as per manufactur-
er’s instructions the kits were as follows; IL-10 (CSB-E12917B) was purchased from Cusabio;
IFN-γ (ESS0026B) from ThermoScientific; and IL-12 paired antibodies (CC301 –capture and
CC326 –detection)were from AbD Serotec. Nitric oxide was measured using a Griess Reagent
Kit (Promega) and arginase levels were determined using the method of [63]. To measure
PD-L1 via qPCR RNA was isolated from cells 6hrs after stimulation and converted to cDNA
using the GoScript Reverse Transcription Kit (Promega). Primers and conditions used are as
previously reported [64].
F. hepatica metacercariae excystment and ADCC killing
F. hepatica metacercariare were obtained from the University of Liverpool clonal strain Fhe-
pLiv and NEJs excysted as previously described [17]. Parasites were rested for 4hrs prior to use
in the ADCC assay which was conducted as previously describedby Piedrafita et al [57] and
Van Milligen et al [65]. Briefly, macrophages were cultured as described above and mixed with
rested NEJs in wells of a 48 well plate containing 40 NEJs and 2 x 105 macrophages per well.
Serumwas collected from three cattle prior to infection and 13 weeks post infection, with 250
metacercariae of F. hepatica (Kind gift from Dr Divya Sachdev University of Nottingham).
Sera was added to wells at a final concentration of 15% in a total volume of 250μl/well. Plates
were incubated for 48hrs and NEJs were observed for viability by monitoring motility, absence
of defined intestinal structures and exclusion of trypan blue. Parasites were only classified as
non-viable if motility and intestinal structure were absent/not visible and trypan blue was
taken up in the tegument. NO was measured in the same supernatant using the methods
above. In some experiments,macrophages were pre-incubated with the inhibitor SB-431542
prior to FhTLM or TGF-β stimulation as described above.
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Statistical analysis
Data was entered into Prism 6.01 (Graphpad) for statistical analysis. Data was analysed using a
1-way Anova with post-test comparison using a Tukey correction. Apart from data in Fig 6
which was analysed using 2-way anova to determine the effect of serum type and macrophage
stimulation. P values<0.05 were taken as significant and individual P values are listed in figure
legends.
Supporting Information
S1 Fig. TGF-β luciferase assay on LFH.MELC luciferase reporter cells were used to test for
the presence of TGF-like molecules in LFH. Cells were cultured in the presence of the indicated
doses of LFH overnight, before luciferase was determined using a luciferase assay on a BMG
luminometer. LFH was tested in triplicate cultures and at least 5 batches were tested.
(TIF)
S2 Fig. Dose dependent induction of IL-10 in bovinemacrophages.Bovinemacrophages,
105/well, were cultured in the presence of increasing doses of FhTLM as indicated. After 48hrs
supernatants were collected and tested for IL-10 by ELISA. Results displayed here represent the
mean +/- SD of triplicate cultures from a single donor, this experiment was repeated five times
with similar outcomes.
(TIF)
S1 Table. Forward and reverse primers used to amplify the extracellularportion of the cor-
responding bovine TGF-β RI or RII.Underlined text corresponds to the restriction site used
for cloning.
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